Jared Gollob - Nov 1, 2021 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Medical Officer
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Stock symbol
KYMR
Transactions as of
Nov 1, 2021
Transactions value $
-$3,506,684
Form type
4
Date filed
11/2/2021, 06:45 PM
Next filing
Mar 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $26.2K +20K +47.01% $1.31* 62.5K Nov 1, 2021 Direct
transaction KYMR Common Stock Options Exercise $9.58K +4.61K +7.37% $2.08* 67.2K Nov 1, 2021 Direct
transaction KYMR Common Stock Sale -$446K -7.39K -11% $60.40 59.8K Nov 1, 2021 Direct F1, F2
transaction KYMR Common Stock Sale -$931K -15.1K -25.32% $61.50 44.6K Nov 1, 2021 Direct F1, F3
transaction KYMR Common Stock Sale -$992K -15.9K -35.65% $62.34 28.7K Nov 1, 2021 Direct F1, F4
transaction KYMR Common Stock Sale -$257K -4.07K -14.15% $63.17 24.7K Nov 1, 2021 Direct F1, F5
transaction KYMR Common Stock Options Exercise $31.2K +15K +60.82% $2.08* 39.7K Nov 2, 2021 Direct
transaction KYMR Common Stock Sale -$535K -8.51K -21.47% $62.89 31.1K Nov 2, 2021 Direct F1, F6
transaction KYMR Common Stock Sale -$335K -5.28K -16.96% $63.50 25.9K Nov 2, 2021 Direct F1, F7
transaction KYMR Common Stock Sale -$77.3K -1.2K -4.65% $64.34 24.7K Nov 2, 2021 Direct F1, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -20K -33.33% $0.00 40K Nov 1, 2021 Common Stock 20K $1.31 Direct F9
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -4.61K -3.33% $0.00 134K Nov 1, 2021 Common Stock 4.61K $2.08 Direct F10
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -15K -11.21% $0.00 119K Nov 2, 2021 Common Stock 15K $2.08 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.01 to $62.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.03 to $63.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.03 to $63.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.13 to $63.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.13 to $64.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F8 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.13 to $64.48. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F9 Twenty-five percent (25%) of the shares underlying this stock option vested on September 12, 2019 and the remaining shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.
F10 The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.